JW PHARMACEUTICAL CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30,400 KRW | +2.01% |
|
+4.29% | -14.49% |
| Mar. 14 | JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 22 | CJ Logistics Secures Distribution Deal for JW Pharm's Intravenous Solutions | MT |
ETFs positioned on JW Pharmaceutical Corporation
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 34 M€ | +2.14% | - |
JW Pharmaceutical Corp is a Korea-based company engaged in the development and manufacture of pharmaceutical products. The Company mainly produces and sells drugs including supplying protein amino acids in blood, blood and fluid substitutes, hyperlipidemia agents, electrolyte additives, angina pectoris agents, rheumatoid arthritis drugs, perfusion fluid, prostatic hypertrophy drugs, hepatic coma drugs, and iron injections, among others. The Company also researches and develops anticancer drugs.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
30,400
KRW
Average target price
41,667
KRW
Spread / Average Target
+37.06%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.49% | 515M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- A001060 Stock
- Funds and ETFs JW Pharmaceutical Corporation
